'''Ricasetron''' ('''BRL-46470''') is a drug which acts as a selective [[Antagonist (pharmacology)|antagonist]] at the [[serotonin]] [[5-HT3 receptor|5-HT<sub>3</sub>]] [[Receptor (biochemistry)|receptor]].<ref name="pmid8413836">{{cite journal |vauthors=Newberry NR, Watkins CJ, Sprosen TS, Blackburn TP, Grahame-Smith DG, Leslie RA |title=BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors |journal=Neuropharmacology |volume=32 |issue=8 |pages=729–35 |date=August 1993 |pmid=8413836 |doi= 10.1016/0028-3908(93)90180-B|url=}}</ref> It has [[antiemetic]] effects as with other 5-HT<sub>3</sub> antagonists,<ref name="pmid7932054">{{cite journal |vauthors=Bermudez J, Sanger GJ |title=Prolonged anti-emetic activity and 5-HT3-receptor antagonism by BRL 46470 in conscious ferrets |journal=The Journal of Pharmacy and Pharmacology |volume=46 |issue=6 |pages=520–1 |date=June 1994 |pmid=7932054 |doi= 10.1111/j.2042-7158.1994.tb03843.x|url=}}</ref> and also has [[anxiolytic]] effects significantly stronger than other related drugs,<ref name="pmid7831418">{{cite journal |vauthors=Blackburn TP, Baxter GS, Kennett GA, King FD, Piper DC, Sanger GJ, Thomas DR, Upton N, Wood MD |title=BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties |journal=Psychopharmacology |volume=110 |issue=3 |pages=257–64 |year=1993 |pmid=7831418 |doi= 10.1007/BF02251279|url=}}</ref> and with less side effects than [[benzodiazepine]] anxiolytics.<ref name="pmid8485019">{{cite journal |vauthors=Link CG, Leigh TJ, Dennison JK |title=The effects of BRL 46470A, a novel 5-HT3 receptor antagonist, and lorazepam on psychometric performance and the EEG |journal=British Journal of Clinical Pharmacology |volume=35 |issue=4 |pages=395–9 |date=April 1993 |pmid=8485019 |pmc=1381550 |doi= 10.1111/j.1365-2125.1993.tb04156.x|url=}}</ref><ref name="pmid8155281">{{cite journal |vauthors=de Souza Silva M, Guimarães FS, Graeff FG, Tomaz C |title=Absence of amnestic effect of an anxiolytic 5-HT3 antagonist (BRL 46470A) injected into basolateral amygdala, as opposed to diazepam |journal=Behavioural Brain Research |volume=59 |issue=1-2 |pages=141–5 |date=December 1993 |pmid=8155281 |doi= 10.1016/0166-4328(93)90160-R|url=}}</ref> However, it has never been developed for medical use.
